Optimising treatment for advanced RCC
Optimising treatment for advanced RCC
Journey through an interactive patient case
Journey through an interactive patient case
Prof. Viktor Grünwald
In this interactive patient case video, you'll meet a 62-year-old man with advanced renal cell carcinoma (RCC) and follow his journey through selection of first- and second-line therapies and managing associated toxicities. Along the way, you'll answer questions at key points, and engage with clickable resources to deepen your understanding of:
- The different efficacy and safety profiles of targeted and immunotherapy treatments for RCC
- How to implement targeted therapies and immunotherapies into treatment strategies for advanced RCC
- Optimal sequencing of treatments
- The cause of toxicities and strategies to improve tolerability and manage side effects whilst maintaining optimal efficacy
Prof. Viktor Grünwald
Medical Oncologist
Universaity Hospital Essen
Germany
Diagnosis and treatment of TRK fusion-positive GI cancers
Interactive patient case | 
11 min
|
Jun 2023
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Clinical Takeaways
-
Current clinical practice for patients with advanced ccRCC is frontline combination of immunotherapy-VEGFR TKI for IDMC intermediate/poor-risk patients
-
Adverse events can generally be managed through dosing strategies, enabling the patient to remain on first-line therapy as long as possible
-
Switching to 2nd line therapy should ideally be at the point of disease progression
This educational programme is supported by an Independent Medical Education Grant from Eisai Europe Limited.
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.
Other programmes of interest
28 min
